Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Endocrine 1

Conditions

Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Hodgkin Disease 1

Interventions

Specimen Handling 456Magnetic Resonance Spectroscopy 347pembrolizumab 287Biopsy 245Carboplatin 228Cisplatin 194Cyclophosphamide 178Paclitaxel 160Nivolumab 153Gemcitabine 147Bevacizumab 126Radiotherapy 124Dexamethasone 110Pemetrexed 101fludarabine 96Fluorouracil 95atezolizumab 93Radiation 92Docetaxel 90venetoclax 89Doxorubicin 88durvalumab 85Oxaliplatin 85Rituximab 84Leucovorin 81Capecitabine 76Prednisone 73Lenalidomide 70X-Rays 69Etoposide 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole × 30 days × Clear all
NCT07460232 2026-05-29

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

Mayo Clinic

Phase EARLY_PHASE1 Recruiting
50 enrolled
Endocrine

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT01476410 2026-05-22

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Northwestern University

Phase 2 Completed
49 enrolled 25 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡